vs

Side-by-side financial comparison of NRX Pharmaceuticals, Inc. (NRXP) and Pelican Acquisition Corp (PELI). Click either name above to swap in a different company.

NRX Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($983.0K vs $888.8K, roughly 1.1× Pelican Acquisition Corp). Pelican Acquisition Corp runs the higher net margin — 57.9% vs 36.7%, a 21.2% gap on every dollar of revenue.

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs in central nervous system disorders, including rare neuropsychiatric conditions. Its main target market is the U.S., with lead product candidates addressing severe mood and trauma-related disorders.

Pelican Products is an American multinational company that designs and manufactures portable lighting systems, temperature controlled packaging and protective cases. Their products are used in many industries including military, law enforcement, fire safety, and consumer entertainment. The company's flagship product, Pelican cases, are molded plastic cases that seal with an airtight and watertight gasket. Pelican is based in Torrance, California. In Europe the products are branded Peli.

NRXP vs PELI — Head-to-Head

Bigger by revenue
NRXP
NRXP
1.1× larger
NRXP
$983.0K
$888.8K
PELI
Higher net margin
PELI
PELI
21.2% more per $
PELI
57.9%
36.7%
NRXP

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
NRXP
NRXP
PELI
PELI
Revenue
$983.0K
$888.8K
Net Profit
$361.0K
$514.6K
Gross Margin
Operating Margin
-42.2%
Net Margin
36.7%
57.9%
Revenue YoY
39.8%
Net Profit YoY
104.0%
67.4%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NRXP
NRXP
PELI
PELI
Q4 25
$983.0K
$888.8K
Q3 25
$242.0K
$635.7K
Q2 25
$0
Q1 25
$0
Q3 24
$0
Net Profit
NRXP
NRXP
PELI
PELI
Q4 25
$361.0K
$514.6K
Q3 25
$-5.9M
$307.4K
Q2 25
$-17.6M
Q1 25
$-5.5M
Q3 24
$-1.6M
Gross Margin
NRXP
NRXP
PELI
PELI
Q4 25
Q3 25
59.9%
Q2 25
Q1 25
Q3 24
Operating Margin
NRXP
NRXP
PELI
PELI
Q4 25
-42.2%
Q3 25
-1662.8%
-52.1%
Q2 25
Q1 25
Q3 24
Net Margin
NRXP
NRXP
PELI
PELI
Q4 25
36.7%
57.9%
Q3 25
-2433.9%
48.4%
Q2 25
Q1 25
Q3 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NRXP
NRXP
PELI
PELI
Cash + ST InvestmentsLiquidity on hand
$7.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-15.9M
$-31.2K
Total Assets
$13.0M
$88.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NRXP
NRXP
PELI
PELI
Q4 25
$7.8M
Q3 25
$7.2M
Q2 25
$2.9M
Q1 25
$5.5M
Q3 24
$1.6M
Stockholders' Equity
NRXP
NRXP
PELI
PELI
Q4 25
$-15.9M
$-31.2K
Q3 25
$-25.8M
$342.9K
Q2 25
$-35.6M
Q1 25
$-25.2M
Q3 24
$-18.8M
Total Assets
NRXP
NRXP
PELI
PELI
Q4 25
$13.0M
$88.1M
Q3 25
$15.0M
$87.3M
Q2 25
$4.8M
Q1 25
$7.6M
Q3 24
$4.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NRXP
NRXP
PELI
PELI
Operating Cash FlowLast quarter
$-3.7M
$-367.8K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-10.29×
-0.71×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NRXP
NRXP
PELI
PELI
Q4 25
$-3.7M
$-367.8K
Q3 25
$-2.9M
$-420.4K
Q2 25
$-4.0M
Q1 25
$-3.5M
Q3 24
$-2.3M
Cash Conversion
NRXP
NRXP
PELI
PELI
Q4 25
-10.29×
-0.71×
Q3 25
-1.37×
Q2 25
Q1 25
Q3 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons